Nipple-Sparing Mastectomy in Patients with Germline BRCA Mutations: Is it Safe?

Richard Gilmore, David M Euhus

Research output: Contribution to journalArticle

Abstract

Through most of recorded medical history, there has been debate about how much healthy tissue should be removed in order to effectively treat breast cancer. The prevailing opinion at the start of the twentieth century was “a lot.” The trend has been reversed in recent decades as advances in systemic treatments and radiation therapy have pushed local recurrence rates down even as breast surgery has become markedly less destructive. There is still debate, however, over the nipple-areolar complex in patients requiring mastectomy. A wealth of data has now accumulated demonstrating that occult nipple involvement with cancer is rare, and usually identifiable in appropriately obtained tissue samples; that leaving the nipple behind does not need to leave a lot of breast tissue behind; that the nipple is not a favored site of recurrence; and that local recurrence rates are quite low in selected breast cancer patients treated with nipple-sparing mastectomy. There has been concern, however, that BRCA gene mutation carriers may be at greater than average risk for new primary breast cancers if the nipple is preserved. Available case series are small and follow-up is short, but thus far, there is no signal to suggest that this is the case. Thorough, oncologically sound nipple-sparing mastectomy appears safe in BRCA gene mutation carriers.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalCurrent Breast Cancer Reports
DOIs
StateAccepted/In press - May 13 2016

Fingerprint

Nipples
Germ-Line Mutation
Mastectomy
Breast Neoplasms
Recurrence
Breast
Mutation
Genes
Radiotherapy
Neoplasms

Keywords

  • BRCA gene mutation carriers
  • Breast cancer
  • Local recurrence
  • Local-regional evaluation
  • Nipple-sparing mastectomy
  • Review

ASJC Scopus subject areas

  • Oncology

Cite this

Nipple-Sparing Mastectomy in Patients with Germline BRCA Mutations : Is it Safe? / Gilmore, Richard; Euhus, David M.

In: Current Breast Cancer Reports, 13.05.2016, p. 1-5.

Research output: Contribution to journalArticle

@article{472c61236e13498f94401b9d6f0b5de7,
title = "Nipple-Sparing Mastectomy in Patients with Germline BRCA Mutations: Is it Safe?",
abstract = "Through most of recorded medical history, there has been debate about how much healthy tissue should be removed in order to effectively treat breast cancer. The prevailing opinion at the start of the twentieth century was “a lot.” The trend has been reversed in recent decades as advances in systemic treatments and radiation therapy have pushed local recurrence rates down even as breast surgery has become markedly less destructive. There is still debate, however, over the nipple-areolar complex in patients requiring mastectomy. A wealth of data has now accumulated demonstrating that occult nipple involvement with cancer is rare, and usually identifiable in appropriately obtained tissue samples; that leaving the nipple behind does not need to leave a lot of breast tissue behind; that the nipple is not a favored site of recurrence; and that local recurrence rates are quite low in selected breast cancer patients treated with nipple-sparing mastectomy. There has been concern, however, that BRCA gene mutation carriers may be at greater than average risk for new primary breast cancers if the nipple is preserved. Available case series are small and follow-up is short, but thus far, there is no signal to suggest that this is the case. Thorough, oncologically sound nipple-sparing mastectomy appears safe in BRCA gene mutation carriers.",
keywords = "BRCA gene mutation carriers, Breast cancer, Local recurrence, Local-regional evaluation, Nipple-sparing mastectomy, Review",
author = "Richard Gilmore and Euhus, {David M}",
year = "2016",
month = "5",
day = "13",
doi = "10.1007/s12609-016-0206-7",
language = "English (US)",
pages = "1--5",
journal = "Current Breast Cancer Reports",
issn = "1943-4588",
publisher = "Current Science, Inc.",

}

TY - JOUR

T1 - Nipple-Sparing Mastectomy in Patients with Germline BRCA Mutations

T2 - Is it Safe?

AU - Gilmore, Richard

AU - Euhus, David M

PY - 2016/5/13

Y1 - 2016/5/13

N2 - Through most of recorded medical history, there has been debate about how much healthy tissue should be removed in order to effectively treat breast cancer. The prevailing opinion at the start of the twentieth century was “a lot.” The trend has been reversed in recent decades as advances in systemic treatments and radiation therapy have pushed local recurrence rates down even as breast surgery has become markedly less destructive. There is still debate, however, over the nipple-areolar complex in patients requiring mastectomy. A wealth of data has now accumulated demonstrating that occult nipple involvement with cancer is rare, and usually identifiable in appropriately obtained tissue samples; that leaving the nipple behind does not need to leave a lot of breast tissue behind; that the nipple is not a favored site of recurrence; and that local recurrence rates are quite low in selected breast cancer patients treated with nipple-sparing mastectomy. There has been concern, however, that BRCA gene mutation carriers may be at greater than average risk for new primary breast cancers if the nipple is preserved. Available case series are small and follow-up is short, but thus far, there is no signal to suggest that this is the case. Thorough, oncologically sound nipple-sparing mastectomy appears safe in BRCA gene mutation carriers.

AB - Through most of recorded medical history, there has been debate about how much healthy tissue should be removed in order to effectively treat breast cancer. The prevailing opinion at the start of the twentieth century was “a lot.” The trend has been reversed in recent decades as advances in systemic treatments and radiation therapy have pushed local recurrence rates down even as breast surgery has become markedly less destructive. There is still debate, however, over the nipple-areolar complex in patients requiring mastectomy. A wealth of data has now accumulated demonstrating that occult nipple involvement with cancer is rare, and usually identifiable in appropriately obtained tissue samples; that leaving the nipple behind does not need to leave a lot of breast tissue behind; that the nipple is not a favored site of recurrence; and that local recurrence rates are quite low in selected breast cancer patients treated with nipple-sparing mastectomy. There has been concern, however, that BRCA gene mutation carriers may be at greater than average risk for new primary breast cancers if the nipple is preserved. Available case series are small and follow-up is short, but thus far, there is no signal to suggest that this is the case. Thorough, oncologically sound nipple-sparing mastectomy appears safe in BRCA gene mutation carriers.

KW - BRCA gene mutation carriers

KW - Breast cancer

KW - Local recurrence

KW - Local-regional evaluation

KW - Nipple-sparing mastectomy

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=84966693610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966693610&partnerID=8YFLogxK

U2 - 10.1007/s12609-016-0206-7

DO - 10.1007/s12609-016-0206-7

M3 - Article

AN - SCOPUS:84966693610

SP - 1

EP - 5

JO - Current Breast Cancer Reports

JF - Current Breast Cancer Reports

SN - 1943-4588

ER -